Trial Profile
A phase II trial of TXA 127 for treatment of Duchenne Muscular Dystrophy
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2017
Price :
$35
*
At a glance
- Drugs Angiotensin-1-7 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- 12 Jun 2017 According to a Tarix Orphan media release, this trial is expected to start in early 2018.
- 27 Jun 2016 According to a Tarix Orphan media release, this trial is expected to initiate in early 2017.
- 17 Feb 2016 According to a Tarix Orphan media release, this trial is expected to start in late 2016.